Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognitive Dysfunction | 15 | 2025 | 1020 | 4.620 |
Why?
|
| Biomarkers | 13 | 2025 | 554 | 3.050 |
Why?
|
| Mindfulness | 5 | 2022 | 33 | 3.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 4 | 2021 | 45 | 2.230 |
Why?
|
| Dementia | 5 | 2024 | 525 | 1.840 |
Why?
|
| Horticultural Therapy | 4 | 2021 | 4 | 1.730 |
Why?
|
| Carnitine | 2 | 2024 | 9 | 1.650 |
Why?
|
| Loneliness | 2 | 2025 | 60 | 1.600 |
Why?
|
| Alzheimer Disease | 8 | 2025 | 2001 | 1.530 |
Why?
|
| Aged | 24 | 2025 | 8433 | 1.440 |
Why?
|
| Aging | 7 | 2025 | 1534 | 1.420 |
Why?
|
| Cognition | 10 | 2024 | 1273 | 1.290 |
Why?
|
| Independent Living | 9 | 2025 | 318 | 1.230 |
Why?
|
| C-Reactive Protein | 3 | 2025 | 95 | 1.160 |
Why?
|
| Humans | 33 | 2025 | 25234 | 1.040 |
Why?
|
| Social Isolation | 2 | 2025 | 28 | 1.010 |
Why?
|
| Saliva | 1 | 2024 | 49 | 0.960 |
Why?
|
| Health Status | 2 | 2024 | 210 | 0.950 |
Why?
|
| Cerebral Palsy | 2 | 2021 | 9 | 0.940 |
Why?
|
| Women's Health | 2 | 2025 | 173 | 0.920 |
Why?
|
| Executive Function | 1 | 2024 | 113 | 0.850 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 1191 | 0.810 |
Why?
|
| Female | 18 | 2025 | 13876 | 0.770 |
Why?
|
| Housing | 1 | 2021 | 15 | 0.770 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 904 | 0.750 |
Why?
|
| Mitochondria, Muscle | 1 | 2020 | 4 | 0.740 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 12 | 0.730 |
Why?
|
| Frailty | 1 | 2020 | 35 | 0.710 |
Why?
|
| Hand Strength | 1 | 2020 | 57 | 0.710 |
Why?
|
| Male | 17 | 2025 | 13575 | 0.700 |
Why?
|
| Sarcopenia | 1 | 2020 | 32 | 0.700 |
Why?
|
| Health Behavior | 1 | 2021 | 145 | 0.700 |
Why?
|
| Mental Health | 2 | 2018 | 105 | 0.690 |
Why?
|
| Depression | 2 | 2020 | 397 | 0.680 |
Why?
|
| Blood Pressure | 1 | 2021 | 201 | 0.680 |
Why?
|
| Quality of Life | 1 | 2024 | 596 | 0.660 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 836 | 0.640 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 4523 | 0.580 |
Why?
|
| Singapore | 5 | 2024 | 9 | 0.570 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 296 | 0.530 |
Why?
|
| Middle Aged | 9 | 2025 | 8145 | 0.500 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 1307 | 0.490 |
Why?
|
| tau Proteins | 2 | 2025 | 221 | 0.430 |
Why?
|
| Pilot Projects | 3 | 2024 | 361 | 0.420 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2022 | 71 | 0.380 |
Why?
|
| Prospective Studies | 2 | 2025 | 1596 | 0.330 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 181 | 0.330 |
Why?
|
| Case-Control Studies | 2 | 2021 | 541 | 0.320 |
Why?
|
| Postmenopause | 2 | 2025 | 51 | 0.300 |
Why?
|
| Chicago | 3 | 2025 | 792 | 0.300 |
Why?
|
| Neurofilament Proteins | 2 | 2025 | 11 | 0.290 |
Why?
|
| Risk Factors | 5 | 2025 | 2175 | 0.270 |
Why?
|
| Inflammation | 2 | 2025 | 255 | 0.260 |
Why?
|
| Leukocyte Count | 1 | 2025 | 62 | 0.240 |
Why?
|
| Arginine | 1 | 2024 | 16 | 0.240 |
Why?
|
| Lysine | 1 | 2024 | 13 | 0.240 |
Why?
|
| Specimen Handling | 1 | 2024 | 40 | 0.240 |
Why?
|
| Consensus | 1 | 2024 | 84 | 0.230 |
Why?
|
| Carbon | 1 | 2024 | 9 | 0.230 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2024 | 32 | 0.230 |
Why?
|
| Phenotype | 2 | 2023 | 285 | 0.220 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 110 | 0.220 |
Why?
|
| Interleukin-6 | 2 | 2021 | 68 | 0.220 |
Why?
|
| Insulin Resistance | 1 | 2023 | 45 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2023 | 395 | 0.210 |
Why?
|
| Research | 1 | 2022 | 34 | 0.210 |
Why?
|
| Incidence | 1 | 2025 | 669 | 0.200 |
Why?
|
| Brain | 3 | 2023 | 1629 | 0.200 |
Why?
|
| Stress, Psychological | 1 | 2024 | 210 | 0.200 |
Why?
|
| Biological Products | 1 | 2022 | 38 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2023 | 121 | 0.190 |
Why?
|
| Social Class | 1 | 2021 | 62 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 328 | 0.190 |
Why?
|
| Immunosenescence | 1 | 2021 | 3 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2025 | 1758 | 0.190 |
Why?
|
| Metabolomics | 1 | 2020 | 19 | 0.180 |
Why?
|
| Fatty Acids | 1 | 2020 | 39 | 0.180 |
Why?
|
| Energy Metabolism | 1 | 2020 | 39 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 167 | 0.180 |
Why?
|
| Health Education | 1 | 2020 | 40 | 0.180 |
Why?
|
| Sex Factors | 1 | 2021 | 430 | 0.170 |
Why?
|
| Intestines | 1 | 2020 | 104 | 0.170 |
Why?
|
| Social Support | 1 | 2020 | 169 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 202 | 0.160 |
Why?
|
| Young Adult | 2 | 2024 | 1751 | 0.160 |
Why?
|
| Publication Bias | 1 | 2019 | 7 | 0.160 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 1038 | 0.160 |
Why?
|
| Amyloid beta-Peptides | 1 | 2020 | 307 | 0.160 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 4 | 0.160 |
Why?
|
| Chemokine CXCL12 | 1 | 2018 | 9 | 0.160 |
Why?
|
| Interleukins | 1 | 2018 | 22 | 0.160 |
Why?
|
| Hydrocortisone | 1 | 2018 | 39 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 727 | 0.150 |
Why?
|
| Interpersonal Relations | 1 | 2018 | 98 | 0.150 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 1622 | 0.150 |
Why?
|
| Anxiety | 1 | 2018 | 136 | 0.140 |
Why?
|
| Animals | 3 | 2023 | 3382 | 0.140 |
Why?
|
| Disease Progression | 1 | 2019 | 652 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 10 | 0.120 |
Why?
|
| Axonal Transport | 1 | 2014 | 6 | 0.120 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2014 | 19 | 0.110 |
Why?
|
| Axons | 1 | 2014 | 23 | 0.110 |
Why?
|
| Adult | 2 | 2024 | 7091 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 233 | 0.100 |
Why?
|
| Neurons | 1 | 2014 | 288 | 0.100 |
Why?
|
| United States | 2 | 2024 | 1906 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 1329 | 0.070 |
Why?
|
| Waist Circumference | 1 | 2023 | 32 | 0.060 |
Why?
|
| Triglycerides | 1 | 2023 | 40 | 0.050 |
Why?
|
| Rural Health | 1 | 2023 | 9 | 0.050 |
Why?
|
| Glucose | 1 | 2023 | 49 | 0.050 |
Why?
|
| Homeostasis | 1 | 2023 | 52 | 0.050 |
Why?
|
| Rural Population | 1 | 2023 | 23 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 10 | 0.050 |
Why?
|
| Memory, Episodic | 1 | 2024 | 118 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2023 | 15 | 0.050 |
Why?
|
| Insulin | 1 | 2023 | 75 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 31 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2023 | 95 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2024 | 597 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 330 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 3 | 0.050 |
Why?
|
| Immunologic Memory | 1 | 2021 | 24 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 34 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 266 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 53 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 109 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 195 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 201 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 721 | 0.040 |
Why?
|
| Research Design | 1 | 2017 | 175 | 0.030 |
Why?
|
| Presenilin-2 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Presenilin-1 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2014 | 18 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2014 | 25 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 99 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 184 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2014 | 468 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 359 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3147 | 0.030 |
Why?
|
| Hippocampus | 1 | 2014 | 248 | 0.020 |
Why?
|
| Mice | 1 | 2014 | 1198 | 0.020 |
Why?
|